INSIGHTS
Client Alerts & Publications
So You Want to Compound a Patented Drug? A Legal Survival Guide for the Brave, the Bold, and the Bewildered
On February 9, 2025, I was watching Super Bowl LIX. On came a commercial by Him & Hers offering to deliver weight loss medications to your door. And they looked a lot like Ozempic® and Wegovy®. Being a pharma patent geek watching with another pharma patent geek, we stopped talking about using MALDI-TOF in infringement analyses and started asking a question that Novo Nordisk single-handedly made vogue last week. Why don’t compounders run afoul of patent law all the time? Or do they?
EMG Case Shines a Light on Sponsor Conflicts in Continuation Fund Transactions
Abu Dhabi Investment Council has filed a complaint against Energy & Minerals Group over a GP-led sale of a 30% stake in Ascent Resources, arguing it would harm limited partners and disproportionately benefit EMG insiders while allowing the fund manager to unjustly reset profit-sharing terms.
The Supreme Court Takes Up “Skinny Labels” and the Fantasy World Where Generics Don’t Compete
The Federal Circuit’s recent decisions have shifted the standards for induced infringement, now considering not just a generic drug's label, but also its marketing practices. This has led to a Supreme Court inquiry on whether a fully carved-out generic label can still encourage infringement.